About
IMVARIA develops FDA-authorized AI-driven digital biomarker software-as-medical-device solutions to enable non-invasive diagnosis and prognosis of lung diseases, including idiopathic pulmonary fibrosis and lung cancer, supporting clinicians in early and accurate clinical decision-making.
Explore IMVARIA's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.